Loading
JPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥1,253
−¥20.00 · -1.57%
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Latest quote
¥1,253
−¥20.00 · -1.57%
Regular session · JST · Market data may be delayed.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Day range
Current ¥1,253
52-week range
Current ¥1,253
Regular session · JST · Market data may be delayed.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Day range
Current ¥1,253
52-week range
Current ¥1,253
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 50.65B JPY | 50.64B JPY | 46.9B JPY | 45.1B JPY | 43.46B JPY |
| Cost of goods sold | 40.75B JPY | 42.17B JPY | 37.22B JPY | 34.95B JPY | 32.16B JPY |
| Gross profit | 9.9B JPY | 8.47B JPY | 9.67B JPY | 10.16B JPY | 11.31B JPY |
| Research and development | — | 2.52B JPY | 2.35B JPY | 1.87B JPY | 1.75B JPY |
| Selling, general, and administrative | 6.26B JPY | 3.33B JPY | 3.43B JPY | 3.08B JPY | 2.99B JPY |
| Operating expenses | 6.26B JPY | 5.85B JPY | 5.78B JPY | 4.94B JPY | 4.74B JPY |
| Interest income | 1M JPY | 1M JPY | — | — | — |
| Interest expense | 130M JPY | 123M JPY | 41M JPY | 12M JPY | 9M JPY |
| Depreciation and amortization | 4.39B JPY | 4.33B JPY | 3.66B JPY | 3.87B JPY | 3.31B JPY |
| Operating income | 3.64B JPY | 2.62B JPY | 3.89B JPY | 5.21B JPY | 6.57B JPY |
| Net income | 3.16B JPY | 1.91B JPY | 3.29B JPY | 3.6B JPY | 4.67B JPY |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 29, 2025 | 2:1 | — | — |
Stock split | Aug 30, 2023 | 11:10 | — | — |
Stock split | Mar 27, 2015 | 11:10 | — | — |
Effective May 29, 2025
2:1
Effective Aug 30, 2023
11:10
Effective Mar 27, 2015
11:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T76.13M0.00%2.91T JPY0.05%¥413.5-0.48%
Vanguard Total International Stock ETFVXUS2.93M0.00%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Developed Markets ETFVEA1.71M0.00%315B USD0.03%$72.69+1.07%
Avantis International Small Cap Value ETFAVDV1.62M0.01%20.6B USD0.36%$111.61+0.72%
Dimensional - International Small Cap Value ETFDISV1.45M0.03%5.24B USD0.42%$44.43+0.77%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS699.43K0.00%13.6B USD0.06%$158.56+0.72%
Schwab International Small-Cap Equity ETFSCHC408.93K0.01%5.68B USD0.06%$50.72+0.63%
Vanguard International Dividend Appreciation ETFVIGI389.44K0.00%9.4B USD0.07%$96.99+0.82%iShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAAvantis International Small Cap Value ETFAVDVDimensional - International Small Cap Value ETFDISVVanguard FTSE All-World ex-US Small-Cap ETFVSSSchwab International Small-Cap Equity ETFSCHCVanguard International Dividend Appreciation ETFVIGIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
